2 results
Approved WMOCompleted
To study the underlying demographic, clinical and pharmacogenetic factors contributing to the failure of achieving analgesia and/or the occurrence of dose-limiting side effects in individual cancer patients for seperate opioids;- To study if theā¦
Approved WMORecruiting
Objective: To compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, withrespect to progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator.